{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-154729","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.586270+00:00","generated_at":"2026-06-01T06:20:15.500147+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya gets $3.85M from Dr. Reddy's for COYA 302 Phase 2 trial; first $6M royalties waived","bullets":["Dr. Reddy's makes $3.85M one-time payment to Coya for funding first Phase 2 trial of COYA 302 in ALS.","Dr. Reddy's has no obligation to pay the first $6M in royalties otherwise due under the DRL Development Agreement.","Amendment effective June 4, 2024; payment due within 5 business days of Coya's invoice.","Funds must be used solely for the Phase 2 trial in the U.S. as per the Development Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-154729","json":"https://secwatch.observer/filing/0001193125-24-154729.json","markdown":"https://secwatch.observer/filing/0001193125-24-154729.md","text":"https://secwatch.observer/filing/0001193125-24-154729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524154729/0001193125-24-154729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312524154729/d838051d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:20:15.500147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}